Welcome to medications.com

BROKERWATCH Novartis cut to 'underweight' vs 'neutral' by HSBC ... - Euro2day

... Aclasta and Exforge treatments and its Tekturna product''s struggle to demonstrate value, having been undermined by cheaper alternatives for Diovan. ...

http://www.euro2day.gr/articlesfn... | Posted: Fri Feb 29 02:40:03 -0500 2008




ADVERTISEMENT
© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com